New study tracks immune therapy results in advanced liver cancer
NCT ID NCT07321067
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow 75 adults with advanced liver cancer who are already receiving immune checkpoint inhibitors as part of their regular care. Researchers will track how long patients live and how long the cancer stays under control. The goal is to better understand the real-world effectiveness of these treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
immune checkpoint inhibitors (e.g., atezolizumab-bevacizumab, durvalumab-tremelimumab)
What this could lead to
If successful, this study could provide real-world data on how well these drugs work for advanced liver cancer, helping guide future treatment decisions.
What could go wrong
This is an observational study, not a controlled trial. Results may be limited by small size (75 people) and lack of a comparison group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sohag university hospitals
Sohag, Sohag Governorate, 82511, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
sSohag oncology centre
Sohag, Sohag Governorate, 82511, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••